High-dose metformin (420mg/kg daily p.o.) increases insulin sensitivity but does not affect neointimal thickness in the rat carotid balloon injury model of restenosis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Metabolism: Clinical and Experimental

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.metabol.2016.12.002PMID 28183442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin as a Tool to Target Aging.

  2016cited by this paper
• Repurposing metformin for cancer treatment: current clinical studies

  2016cited by this paper
• Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission

  2016cited by this paper
• Inhibition of the Inflammasome NLRP3 by Arglabin Attenuates Inflammation, Protects Pancreatic β-Cells from Apoptosis, and Prevents Type 2 Diabetes Mellitus Development in ApoE2Ki Mice on a Chronic High-Fat Diet

  2016cited by this paper
• TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes.

  2015cited by this paper
• Metformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis

  2014cited by this paper
• Supplemental Figure 1

  2014cited by this paper
• Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

  2014cited by this paper
• The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats

  2013cited by this paper
• GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.

  2013cited by this paper
• AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury.

  2013cited by this paper
• Protective Effect of Metformin on Myocardial Injury in Metabolic Syndrome Patients following Percutaneous Coronary Intervention

  2013cited by this paper
• Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation.

  2013cited by this paper
• PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.

  2012cited by this paper
• Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases

  2012cited by this paper
• Ceramide Mediates Vascular Dysfunction in Diet-Induced Obesity by PP2A-Mediated Dephosphorylation of the eNOS-Akt Complex

  2012cited by this paper
• Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism.

  2012cited by this paper
• Restenosis after PCI. Part 1: pathophysiology and risk factors

  2012cited by this paper
• Metformin-induced AMP-activated protein kinase activation regulates phenylephrine-mediated contraction of rat aorta.

  2012cited by this paper
• Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells.

  2012cited by this paper
• Hydrogen-rich saline prevents neointima formation after carotid balloon injury by suppressing ROS and the TNF-α/NF-κB pathway.

  2012cited by this paper
• SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.

  2012cited by this paper
• Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP

  2012cited by this paper
• Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice.

  2011cited by this paper
• AMPK 2 Deletion Exacerbates Neointima Formation by Upregulating Skp2 in Vascular Smooth Muscle Cells

  2011cited by this paper
• Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

  2010cited by this paper
• Insulin Inhibits and Oral Sucrose Increases Neointimal Growth after Arterial Injury in Rats

  2010cited by this paper
• Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation

  2010cited by this paper
• Nonesterified fatty acid exposure activates protective and mitogenic pathways in vascular smooth muscle cells by alternate signaling pathways.

  2009cited by this paper
• Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio.

  2009cited by this paper
• The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus

  2009cited by this paper
• Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000–2007

  2008cited by this paper
• METFORMIN, ARTERIAL FUNCTION, INTIMA–MEDIA THICKNESS AND NITROXIDATION IN METABOLIC SYNDROME: THE MEFISTO STUDY

  2008cited by this paper
• Integrin-linked kinase in the vascular smooth muscle cell response to injury.

  2008cited by this paper
• Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience

  2007cited by this paper
• AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner

  2007cited by this paper
• The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin

  2005cited by this paper
• Anti-Atherogenic Effect of Insulin in vivo

  2005cited by this paper
• Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction

  2005cited by this paper
• Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention.

  2004cited by this paper
• Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo

  2004cited by this paper
• Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy

  2004cited by this paper
• AMP-Activated Protein Kinase Inhibits Angiotensin II– Stimulated Vascular Smooth Muscle Cell Proliferation

  2004cited by this paper
• Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.

  2004cited by this paper
• Troglitazone Stimulates Repair of the Endothelium and Inhibits Neointimal Formation in Denuded Rat Aorta

  2003cited by this paper
• Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients.

  2002cited by this paper
• The mechanisms of coronary restenosis: insights from experimental models

  2000cited by this paper
• 8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo.

  2000cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury.

  1996cited by this paper
• Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats.

  1994cited by this paper
• Hypertension and sympathetic hyperactivity induced in rats by high-fat or glucose diets.

  1991cited by this paper
• Development of Muscle Insulin Resistance After Liver Insulin Resistance in High-Fat–Fed Rats

  1991cited by this paper
• Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits.

  1983cited by this paper

• Mechanisms and therapeutic opportunities in metabolic aberrations of diabetic wounds: a narrative review

  2025cites this paper
• Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet

  2024cites this paper
• Vascular smooth muscle cells in intimal hyperplasia, an update

  2023cites this paper
• Metformin and Gegen Qinlian Decoction boost islet α-cell proliferation of the STZ induced diabetic rats

  2022cites this paper
• Metformin Attenuates Hypoxia-induced Endothelial Cell Injury by Activating the AMP-Activated Protein Kinase Pathway

  2021cites this paper
• Resveratrol Inhibits Neointimal Growth after Arterial Injury in High-Fat-Fed Rodents: The Roles of SIRT1 and AMPK

  2020cites this paper
• Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function

  2020influential citation
• Catalpol Ameliorates Neointimal Hyperplasia in Diabetic Rats

  2019cites this paper
• Effects of metformin on metabolism of white and brown adipose tissue in obese C57BL/6J mice

  2019cites this paper
• Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats.

  2019cites this paper